Author pages are created from data sourced from our academic publisher partnerships and public sources.
The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy
- J. V. van Beijnum, P. Nowak-Śliwińska, E. J. Huijbers, V. Thijssen, A. Griffioen
- Pharmacological Reviews
- 1 April 2015
The concept of antiangiogenic therapy in cancer treatment has led to the approval of different agents, most of them targeting the well known vascular endothelial growth factor pathway. Despite… Expand
Vaccination approach to anti-angiogenic treatment of cancer.
- M. Q. Wentink, E. J. Huijbers, T. D. de Gruijl, H. Verheul, A. Olsson, A. Griffioen
- Biology, Medicine
- Biochimica et biophysica acta
- 1 April 2015
Improvement of patient survival by anti-angiogenic therapy has proven limited. A vaccination approach inducing an immune response against the tumor vasculature combines the benefits of immunotherapy… Expand
Role of the tumor stroma in resistance to anti-angiogenic therapy.
- E. J. Huijbers, J. V. van Beijnum, V. Thijssen, S. Sabrkhany, P. Nowak-Śliwińska, A. Griffioen
- Biology, Medicine
- Drug resistance updates : reviews and…
- 1 March 2016
Several angiogenesis inhibitors are currently used in the clinic for treatment of cancer. While anti-angiogenesis treatment can improve treatment outcome, the overall benefit on patient survival is… Expand
CD44 enhances tumor aggressiveness by promoting tumor cell plasticity
Aggressive tumor cells can obtain the ability to transdifferentiate into cells with endothelial features and thus form vasculogenic networks. This phenomenon, called vasculogenic mimicry (VM), is… Expand
Vaccination against the extra domain‐B of fibronectin as a novel tumor therapy
- E. J. Huijbers, M. Ringvall, +5 authors Anna-Karin Olsson
- FASEB journal : official publication of the…
- 1 November 2010
Monoclonal antibody‐based therapies have made an important contribution to current treatment strategies for cancer and autoimmune disease. However, the cost for these new drugs puts a significant… Expand
Identification of potent biodegradable adjuvants that efficiently break self-tolerance--a key issue in the development of therapeutic vaccines.
Monoclonal antibodies are used successfully in the treatment of many human disorders. However, these antibodies are expensive and have in many countries put a major strain on the health care economy.… Expand
Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer
Therapeutic vaccination targeting self-molecules is an attractive alternative to monoclonal antibody-based therapies for cancer and various inflammatory diseases. However, development of cancer… Expand
Targeting Serglycin Prevents Metastasis in Murine Mammary Carcinoma
In hematopoietic cells, serglycin proteoglycans mainly contribute to proper storage and secretion of inflammatory mediators via their negatively charged glycosaminoglycans. Serglycin proteoglycans… Expand
The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development.
- E. J. Huijbers, Julia Femel, K. Andersson, H. Björkelund, L. Hellman, A. Olsson
- 5 January 2012
We have recently shown that immunization against the extra domain-B (ED-B) of fibronectin, using Freund's adjuvant, reduces tumor growth in mice by 70%. In the present study we compare the immune… Expand
An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature.
The induction of an antibody response against self-antigens requires a conjugate vaccine technology, where the self-antigen is conjugated to a foreign protein sequence, and the co-application of a… Expand